Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma

Cell Death and Disease

Volumn 9, Issue 1, 2018, Pages

  Redlich, Nathan ^a   Robinson, Anthony M ^b   Nickel, Kwangok P ^c,d   Stein, Andrew P ^e   Wheeler, Deric L ^c,d   Adkins, Douglas R ^b   Uppaluri, Ravindra ^f   Kimple, Randall J ^c,d   Van Tine, Brian A ^b   Michel, Loren S ^g  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB3 ANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; TROP2 ANTIBODY; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; CETUXIMAB; COBALT; COBALT CHLORIDE; NRG1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

3T3 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; GENETICS; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CETUXIMAB; COBALT; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEUREGULIN-1; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-3; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK; TRANSPLANTATION, HETEROLOGOUS;

EID: 85040347166     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-017-0029-0     Document Type: Article

References (53)

1. Gillison, M. L. et al. Evidence for a causal association between human papil-lomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92, 709�720 (2000).
2. Chan, A. T., Teo, P. M. & Johnson, P. J. Nasopharyngeal carcinoma. Ann. Oncol. 13, 1007�1015 (2002).
3. Rothenberg, S. M. & Ellisen, L. W. The molecular pathogenesis of head and neck squamous cell carcinoma. J. Clin. Invest. 122, 1951�1957 (2012).
4. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157�1160 (2011).
5. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154�1157 (2011).
6. Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121�1134 (2012).
7. Lui, V. W. et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3, 761�769 (2013).
8. Pickering, C. R. et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 3, 770�781 (2013).
9. Nichols, A. C. et al. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol. Head Neck Surg. 139, 617�622 (2013).
10. Hedberg, M. L. et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J. Clin. Invest. 126, 1606 (2016).
11. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576�582 (2015).
12. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567�578 (2006).
13. Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116�1127 (2008).
14. Iida, M. et al. Targeting the HER Family with Pan-HER effectively overcomes resistance to cetuximab. Mol. Cancer. Ther. 15, 2175�2186 (2016).
15. Francis, D. M. et al. Pan-HER inhibitor augments radiation response in human lung and head and neck cancer models. Clin. Cancer Res. 22, 633�643 (2016).
16. Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437�441 (2007).
17. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039�1043 (2007).
18. Wheeler, D. L. et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27, 3944�3956 (2008).
19. Schoeberl, B. et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70, 2485�2494 (2010).
20. Sun, C. et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7, 86�93 (2014).
21. Morrison, M. M. et al. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J. Clin. Invest. 123, 4329�4343 (2013).
22. Cook, R. S. et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res. 71, 3941�3951 (2011).
23. Young, C. D. et al. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res. 73, 4075�4085 (2013).
24. Lee, D. et al. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J. Clin. Invest. 119, 2702�2713 (2009).
25. Jaiswal, B. S. et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603�617 (2013).
26. Schaefer, G. et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472�486 (2011).
27. Huang, S. et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73, 824�833 (2013).
28. Li, C. et al. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov. Med. 16, 79�92 (2013).
29. Jiang, N. et al. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol. Cancer Ther. 13, 1826�1836 (2014).
30. Zhang, L. et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol. Cancer Ther. 13, 1345�1355 (2014).
31. Ma, J., Lyu, H., Huang, J. & Liu, B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol. Cancer 13, 105 (2014).
32. Fitzgerald, J. B. et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol. Cancer Ther. 13, 410�425 (2014).
33. Fayette, J. et al. Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study). Front. Oncol. 6, 232 (2016).
34. Wang, J., Day, R., Dong, Y., Weintraub, S. J. & Michel, L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol. Cancer Ther. 7, 280�285 (2008).
35. Wang, J. et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol. Cancer Res. 9, 1686�1695 (2011).
36. Stoyanova, T. et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev. 26, 2271�2285 (2012).
37. Trerotola, M. et al. Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget 6, 14318�14328 (2015).
38. Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180, 599�607 (2012).
39. Ang, K. K. et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62, 7350�7356 (2002).
40. Kimple, R. J. et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin. Cancer Res. 19, 855�864 (2013).
41. Qian, G. et al. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Cancer 121, 3600�3611 (2015).
42. Zhang, K. et al. Loss of Trop2 causes ErbB3 activation through a neuregulin-1dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget 5, 9281�9294 (2014).
43. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480�1486 (2014).
44. Brand, T. M. et al. AXL mediates resistance to cetuximab therapy. Cancer Res. 74, 5152�5164 (2014).
45. Costa, C. et al. Measurement of PIP3 levels reveals an unexpected role for p110beta in early adaptive responses to p110alpha-specific inhibitors in luminal breast cancer. Cancer Cell 27, 97�108 (2015).
46. Humtsoe, J. O., Pham, E., Louie, R. J., Chan, D. A. & Kramer, R. H. ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth. Oncogene 35, 1554�1564 (2016).
47. Heeg, S. et al. EGFR overexpression induces activation of telomerase via PI3K/ AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis. Cancer Sci. 102, 351�360 (2011).
48. Citri, A. & Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell. Biol. 7, 505�516 (2006).
49. Saffarian, S., Li, Y., Elson, E. L. & Pike, L. J. Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis. Biophys. J. 93, 1021�1031 (2007).
50. Steinkamp, M. P. et al. erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol. Cell. Biol. 34, 965�977 (2014).
51. Yang, C., Liu, Y., Lemmon, M. A. & Kazanietz, M. G. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol. Cell. Biol. 26, 831�842 (2006).
52. Shames, D. S. et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS ONE 8, e56765 (2013).
53. Nilsson, M. B. et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for anti-angiogenic mechanisms of multikinase inhibitors. Oncogene 29, 2938�2949 (2010).